Advertisement

Annals of Surgical Oncology

, Volume 12, Issue 7, pp 511–512 | Cite as

Antitumor Vaccines: Of Mice and Men?

Editorial
  • 35 Downloads

Keywords

Trastuzumab Vaccine Therapy Immunogenic Tumor Major Histocompatibility Class Passive Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17PubMedGoogle Scholar
  2. 2.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48PubMedGoogle Scholar
  3. 3.
    Mocellin S, Mandrzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumors. Lancet Oncol 2004;5:681–9CrossRefPubMedGoogle Scholar
  4. 4.
    Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539–46Google Scholar
  5. 5.
    Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148–57PubMedGoogle Scholar
  6. 6.
    Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–80Google Scholar
  7. 7.
    Mapura MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51CrossRefPubMedGoogle Scholar
  8. 8.
    Viehl CT, Becker-Hapak M, Lewis JS, et al. A Tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (in press)Google Scholar
  9. 9.
    Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859–66PubMedGoogle Scholar
  10. 10.
    Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57:579–96CrossRefPubMedGoogle Scholar
  11. 11.
    Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005;86:241–305CrossRefPubMedGoogle Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2005

Authors and Affiliations

  1. 1.Department of SurgeryNew York University School of MedicineNew York

Personalised recommendations